Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study

Giammaria Fiorentini, Camillo Aliberti, Gina Turrisi, Alessandro Del Conte, Susanna Rossi, Giorgio Benea, Petros Giovanis

Research output: Contribution to journalArticle

Abstract

Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80%), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC.

Original languageEnglish
Pages (from-to)1085-1092
Number of pages8
JournalIn Vivo
Volume21
Issue number6
Publication statusPublished - Nov 2007

Keywords

  • Colorectal cancer
  • DC beads
  • Hepatic angiography
  • Intraarterial chemotherapy
  • Irinotecan
  • Liver metastasis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study'. Together they form a unique fingerprint.

  • Cite this

    Fiorentini, G., Aliberti, C., Turrisi, G., Del Conte, A., Rossi, S., Benea, G., & Giovanis, P. (2007). Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. In Vivo, 21(6), 1085-1092.